// App-Quantinova.ai

e15527 : Baseline high-sensitivity C-reactive protein to predict progression-free survival in metastatic renal cell carcinoma patients treated with first-line sunitinib.

Researchers

Presenter

  • Ryuichi Mizuno

Principal Investigators

  • Go Kimura

  • Tsunenori Kondo

  • Kazuhiro Matsumoto

  • Masaru Ishida

  • Shunji Takahashi

  • Kazunari Tanabe

  • Hayakazu Nakazawa

  • Shigeo Horie

  • Mototsugu Oya

  • Takeshi Ueda

  • Hidehiko Hara

  • Takeshi Kishida

  • Haruki Kume

  • Sunao Sohji

  • Takashi Hatano

  • Jun Morita

  • Nozomu Kawata

Medical Centers

  • Department of Breast Surgery, Kyorin University, Tokyo, Japan

  • Department of Neurosurgery, Tokyo Women's Medical University, Tokyo, Japan

  • Keio University School of Medicine, Department of Urology, Tokyo, Japan

  • Department of Urology, Surugadai Nihon University Hospital, Tokyo, Japan

  • Department of Surgery, Saiseikai Yokohamashi Nanbu Hospital, Yokohama City, Japan

  • The Jikei University School of Medicine, Tokyo, Japan

  • Nippon Medical School, Tokyo, Japan

  • Tokyo Women's Medical University Medical Center East, Tokyo, Japan

  • Department of Medical Oncology, Kyorin University School of Medicine, Tokyo, Japan

  • Department of Urology, Tokyo Saiseikai Central Hospital, Tokyo, Japan

  • Department of Pharmacy,The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • Metastatic Renal Cell Cancer

Biomarkers

  • High sensitivity C-reactive protein

Drug/Treatment

  • ILS-969

  • Sunitinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • UMIN000009622

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved